Foley Mark J (CIK 1529196) reported 13 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-06-01). Recent activity: Buy GKOS (1,878 shares), Buy GKOS (1,168 shares), Buy GKOS (864 shares), Buy GKOS (2,108 shares), Buy GKOS (25,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-01 | GLAUKOS Corp (GKOS) | Director | Buy | 1,878 | $0 |
| 2026-01-07 | GLAUKOS Corp (GKOS) | Director | Buy | 1,168 | $0 |
| 2025-06-02 | GLAUKOS Corp (GKOS) | Director | Buy | 864 | $0 |
| 2025-06-02 | GLAUKOS Corp (GKOS) | Director | Buy | 2,108 | $0 |
| 2025-02-28 | GLAUKOS Corp (GKOS) | Director | Buy | 25,000 | $800,000 |
| 2025-02-28 | GLAUKOS Corp (GKOS) | Director | Buy | 15,000 | $370,350 |
| 2025-02-28 | GLAUKOS Corp (GKOS) | Director | Sell | 20,687 | $2.5M |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | President & CEO | Sell | 996,935 | $3.6M |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | President & CEO | Sell | 110,913 | $404,832 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | President & CEO | Sell | 27,933 | $0 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | President & CEO | Buy | 84,686 | $0 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | President & CEO | Sell | 84,686 | $0 |
| 2025-02-05 | Revance Therapeutics, Inc. (RVNC) | CEO | Buy | 27,933 | $0 |
Source: SEC Form 4 filings · as of 2026-06-01